Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Augustine Duffy
Institution:
Georgia Institute of Technology
Observed institution:
Georgia Institute of Technology
ORCID:
0009-0007-4984-4633
Observed ORCID:
0009-0007-4984-4633
OpenAlex ID:
A5063762818
Broad protection against clade 1 sarbecoviruses after a single immunization with cocktail spike-protein-nanoparticle vaccine
2024
·
Peter J. Halfmann
, Kathryn Loeffler
, et al.
·
Nature Communications
·
33
PDF
Merbecovirus S2 subunit vaccines elicit cross reactive antibodies and provide partial protection against MERS coronavirus
2025
·
Peter J. Halfmann
, Jeong Soo Lee
, et al.
·
npj Viruses
·
8
Hemagglutinin-displaying influenza nanovaccines: progress and promise
2025
·
Donguk Kim
, Augustine Duffy
, et al.
·
Nanomedicine
·
3
PDF
Inverted H1 hemagglutinin nanoparticle vaccines protect mice against challenges with human H1N1 and bovine H5N1 influenza viruses
2025
·
Asim Biswas
, Kathryn Loeffler
, et al.
·
npj Vaccines
·
2
PDF
Immunogenicity and protective efficacy of MERS CoV, NL140422, and HKU4 spike protein nanoparticle vaccines
2026
·
Peter J. Halfmann
, Jeong Soo Lee
, et al.
·
npj Viruses
·
1
PDF
Characterization and immunogenicity of nanoparticle vaccines based on Clade 2 and Clade 3 sarbecovirus S2 proteins
2025
·
Peter J. Halfmann
, Raj S. Patel
, et al.
·
npj Vaccines
·
1
PDF
Characterization of Immune Responses to RBD‐SD1 Nanoparticle Vaccines Derived From ACE2‐Capable HKU5‐CoV‐2, NeoCoV, and HKU5 Merbecoviruses
2026
·
Peter J. Halfmann
, Jeong Soo Lee
, et al.
·
Biotechnology and Bioengineering
Characterization and immunogenicity of nanoparticle vaccines displaying embecovirus spike proteins
2026
·
Peter J. Halfmann
, Augustine Duffy
, et al.
·
Biotechnology Progress
Evaluating the immunogenicity of clade 2 and clade 3 sarbecovirus spike protein nanoparticle vaccines in Syrian hamsters
2026
·
Peter J. Halfmann
, Augustine Duffy
, et al.
·
Vaccine
RBD‐SD1 Nanoparticle Vaccines From DPP4‐Using Merbecoviruses Elicit a Cross‐Reactive Antibody Response but Limited Cross‐Protective Immunity
2026
·
Peter J. Halfmann
, Jeong Soo Lee
, et al.
·
Biotechnology and Bioengineering
Show more works
View as search
Works count:
10
Citation count:
48
H-index:
3
I10-index:
1
Year
Topic
Type